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INTRODUCTION 
Systemic Lupus Erythematosus  (SLE) is an autoimmune disease in 
which organs, tissues, and cells undergo damage mediated by tissue-
binding auto-antibodies and immune complexes. 
Many of its clinical manifestations are secondary to the trapping of 
antigen-antibody complexes in capillaries of visceral structures or to auto 
antibody-mediated destruction of host cells. The clinical course is marked 
by spontaneous remission and relapses. The severity may vary from a 
mild episodic disorder to a rapidly  fulminant,  life -threatening  illness. 
The lungs may conveniently be considered in six main regions: the 
pleural space, the parenchyma, the pulmonary vasculature, the airways, 
the diaphragm, and the chest wall including the ribs and respiratory 
muscles. Systemic Lupus Erythematosus (SLE) and the adverse effects of 
various therapies may affect all these regions of the chest. 
Pulmonary involvement is common in SLE and will affect half of 
patients during the disease course and is part of the spectrum of 
presenting symptoms in 4% to 5% of patients1. 
Primary involvement of the lung and pleurae is common in SLE. 
The clinical presentation are protean and sometimes are presenting 
feature of the disease. Subclinical involvement also is prevalent, as shown 
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by the high frequency of the abnormal pulmonary function  test results in 
patient who are free from respiratory complaints. 
Furthermore, other complications of lupus such as cardiac failure 
or nephritic syndrome may lead to lung involvement with the 
development of pleural effusions. Pulmonary involvement may increase 
the risk of mortality; in one study, lung involvement was one of several 
factors that was predictive for increased mortality2. 
The prevalence of pulmonary manifestations in SLE depends on 
the referral pattern to the unit where patients are studied, the population 
under scrutiny, and the methods used to detect pulmonary involvement. 
This study has been conducted to evaluate the pulmonary 
manifestations in SLE patients and to correlate  the clinical features with 
radiographic  findings and pulmonary function tests. The usefulness of 
the high resolution computed  tomography  (HRCT) , which is reported to 
be promising in the diagnosis, and the disease activity in the lung 
parenchyma , needs a special mention. 
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AIM OF THE STUDY 
1. To study the prevalence of respiratory abnormalities in 
Systemic Lupus  Erythematosus . 
2. To  correlate  the  clinical  features with  Plain radiographs, 
Pulmonary  function  tests(PFT)  and high  resolution  
computed  tomography (HRCT). 
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REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
The combinations of Osler  and  Jadasson established that SLE was 
a distinct syndrome, and in 1904  Osler3 described the occurrence of 
pneumonia  in SLE . Further reports in the 1930s and 1940s described 
polyserositis , patchy lung consolidation , and other pulmonary changes 
including  “atelectizing pneumonitis” in patients with  SLE4,5. Autopsy of 
these patients showed diffuse lung consolidation with hyaline alveolar 
thickening and marked obliterating cellular infiltration. Baggentoss 
entended these observations and observed a peculiar basophilic, 
mucinous edema of the alveolar walls and the peribronchial and  
perivascular tissues in association with interstitial  pneumonitis and 
alveolar  hemorrhage. These pathologic changes were distinct from the 
ordinary pyogenic and fibrinous bronchopneumonia that frequently 
complicates  the terminal stages of SLE, but they were not 
pathognomonic of SLE6. In  atelectizing  pneumonitis ,the alveolar walls 
as well as the peribronchial and perivascular  connective tissues  appeared  
to be the primary sites of an inflammatory process that obliterated 
alveolar spaces. 
In 1953 and 1954, two patients of radiographic studies in SLE 
emphasized the high frequency of pulmonary involvement. Israel7 
showed. That non specific pneumonia occurred frequently, not only 
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during the terminal stages of SLE but throughout the course of the 
disease. Garland and Sisson8 reported lung  parenchymal  changes in one 
third of their patients and observed  both pleural and cardiac 
abnormalities to be prevalent .Comprehensive reviews of the pulmonary 
manifestations of SLE in adults9-11 and in children12 have appeared.  
PATHOLOGY  
A wide variety of lesions have been described in the lungs, but 
none are specific for SLE .For example ,an autopsy study of 54 patients 
showed the following pathologic abnormalities in more than 50% of 
cases: bronchopneumonia, hemorrhage, pleural effusion, edema, 
interstitial pneumonia, and congestion6.  Fibrinoid necrosis and  
hemotoxylin bodies were  seen13, where as bronchiolar dilation and  foci 
of  panacinar emphysema  were found14. Fayemi15 1 noted the high 
frequency of occlusive  vascular changes of  varying severity in the lungs 
of 7 of 20 patients  with SLE; these affected  arterioles, arteries and veins. 
The acute lesion consist of  fibrinoid  necrosis and  vasculitis , and the 
chronic lesions included  intimal  fibrosis, medial hypertrophy, alteration 
of the elastic laminae  and periadventitial  fibrosis.  Haupt et al.,16 
examined pathological  changes in the lungs of 120 patients seen in the 
autopsy and correlate  with the clinical features .In contrast to the high 
frequency lung involvement  in clinical series9, they showed many of the 
pathological changes  are not caused by SLE itself, but rather by the 
secondary factors, such as congestive heart failure ,infection, aspiration 
and oxygen toxicity. 
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Only 18% of the lung parenchymal lesion were directly attributable 
to SLE. Although informative, analyse of the autopsy cases may not 
represent a cross-section of the general population of lupus patients and 
probably underestimate the prevalence of lung involvement. Certainly in 
the clinical setting, pulmonary abnormalities can change rapidly and 
subside either spontaneously or with drug therapy, so anatomic lesions 
may not be evident  later at autopsy. 
THE CLINICAL ASSESSMENT OF PULMONARY 
INVOLVEMENT 
As with any other branch of medicine the clinical assessment of 
pulmonary  disease in lupus patients is based on careful history, thorough 
examination , and  appropriate further investigations. 
     A useful screening question is, have you been shortness of breath or 
had chest  pain ? The most early symptom of serositis is chest pains, 
which occur on both inspiration and expiration. There is nothing 
particular about the pain that differentiates lupus from other causes of 
pleurisy such as infection or pulmonary embolism. resolution of pleuritic 
pain does not always imply improvement since pain at a particular site of 
the chest may disappear if a significant pleural effusion develops. 
Dyspnoea may be the presenting symptom of many of the other 
complications of lupus to affect the lung. A sudden onset is more likely to 
be due to pulmonary embolism, but the more usual presentation is an 
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insidious onset of breathlessness. An estimate of patients walking 
distance may is a useful guide to exercise tolerance and the extend of 
lung involvement.  Hemoptysis may be the presenting feature of infection 
, infarction ,cardiac failure, or very rarely pulmonary hemorrhage.      
Clinically a  thorough cardiac assessment is essential, with particular 
attention to signs of cardiac valve disease , left or right ventricular failure, 
and pointer towards pulmonary  hypertension. 
INVESTIGATION OF PULMONARY INVOLVEMENT 
CHEST RADIOGRAPH 
The chest radiograph is a simple and useful extension of the 
clinical Examination of the patient with SLE. Previous films, when 
available, may give valuable information on disease progression or the 
appearance of new lesions.  
Abnormalities on chest radiographs are reasonably common in 
patient with SLE. For example, in a prospective study of 50 unselected 
patients, abnormalities were found in 38%17, and in a study  of 43 patients 
who were examined specifically for pulmonary  dysfunction, 23% had 
abnormal chest radiographs18. In contrast , none of 70 nonsmoking 
patients with SLE who were  free of respiratory  complaints and enrolled  
in a study of pulmonary function had abnormal chest  radiographs27. 
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A   wide array of abnormalities can be seen in chest radiographs. 
Early studies  thoroughly and meticulously documented radiographic 
changes in the  pleura ,lung parenchyma and heart. Pleural changes as an 
isolated abnormality or in combination with cardiac or  parenchymal  
lesions are the most common radiographic changes19,20. The pleura  may 
appear as a shaggy thickening of the pleural surface. Pleural effusions are 
small, and  in 50% of patients, bilateral. Parenchymal lesions are 
characterized by ill defined focal patches, linear bands, infiltrates, small 
nodules, or plagues in the bases. Diffuse, granular, reticular, or 
reticulonodular lesions throughout the lung fields, but more prominent at 
the bases, are found in a small number of patients with SLE and chronic 
interstitial fibrosis.  Cardiomegaly  in minimal to  moderate  . Elevated 
diaphragms are found in 5-18% of patients21. 
In 111 patients with SLE, Levin22 found that radiographic  
parenchymal changes (infiltrates or small nodules) were mostly result of  
secondary complications, such as infections, uremic pulmonary edema, 
and basilar atelectasis . Primary lupus pneumonitis was relatively rare, 
being found only three patients (2.7%) patients, and the diagnosis 
therefore became one of the exclusion. 
PULMONARY FUNCTION TEST 
Simple spirometry gives useful information on the pattern of 
pulmonary involvement. The ratio of 1 – sec Forced Expiratory Volume 
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to Forced Vital Capacity (FEV1/FVC) distinguishes restrictive patterns , 
most often due to the interstitial lung disease, from obstructive patterns 
due to lesions  that may affect the larger airways as well as documenting 
lung volumes .  
            PFT abnormalities are exceeding common in patients with SLE, 
even in those  without history   of  respiratory  complaints  and  with  
normal chest radiographic findings. An impaired diffusing capacity, 
reduction in lung volume and hypoxia are the common abnormalities. 
      In 1996, Gold and Jennings23 carried out PFT since 20 patients with 
SLE and respiratory symptoms and found evidence for three major 
changes:(1)restrictive  disease, (2) airway obstruction and (3)  pulmonary 
vascular  obstruction. Twelve of the patients had evidence of restrictive 
disease, 3 had severe  airway obstruction without  pulmonary restriction, 
and 5 had pulmonary vascular obstruction. Three patients died and the 
pathologic findings in the lungs correlated with the physiologic 
abnormalities observed during life. 
Wohlgelernter  et al.,24 found   PFT  abnormalities in 90% of their  
patients with SLE and a previous history of  pleuritis and/or   pneumonitis 
and in 71% of their without pulmonary complaints. The most common 
abnormalities were a decreased % Diffusion Capacity of carbonmonoxide 
(DLCO), lack of  response to breathing helium , restrictive  ventilatory 
defect ,   and arterial  hypoxemia.    None of their patients with chronic 
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discoid LE had an abnormal PFT, which is a finding consistent with the 
limited disease process in this condition. In a prospective study of 43 
ambulatory, consecutive patients with SLE. 
 Silberstein et al.,25 attempted to correlate PFT abnormalities with  
other  measures of lupus activity. Pulmonary dysfunction was noted in 
88% of the  patients. An impaired %  DLCO(72% of all patients) 
,reduction in lung  volume(49%) ,and hypoxia(44%) were the most 
common abnormalities that  were found. No Correlation was found 
among the type and severity of the abnormality  and with serum 
complement levels, anti DNA antibody , lupus-band  test and nephritis. 
Patients with SLE and abnormal PFT results did not differ  from those 
with normal PFT results in regard to their clinical features and  
immunologic   findings . 
In contrast,  Holgate et al.,26 reported that the patients  with SLE 
and prominent pleuro-pulmonary disease had a lower prevalence of lupus  
nephritis, suggesting that this is partly a result of the low frequency of 
anti-DNA antibodies in this group of patients. 
            Andronopoulos et al27.,conducted the largest controlled study of 
PFTs in patients with SLE to date. They studied 70 lifelong nonsmoking 
patients with SLE and an equal number of age and sex matched, non-
smoking healthy subjects. None of the patients had active pulmonary 
disease, and all had normal chest radiographs at the time of the study. An 
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isolated reduction in the %DLCO was the most prevalent abnormality 
found in the patients with SLE (31%), but it was not found in the 
controls. Isolated small airway disease, which was defined as less than 
60% of the predicted value of the maximal flow at 25% of vital capacity, 
was common in both patients with SLE (24%) and controls 
(17%).Restrictive and obstructive patterns were  uncommon in SLE , 
being seen in only 5.7% of patients. Overall, only  33% of the patients 
with SLE had normal PFT results, compared with 83% of controls. 
           Eichacker et al.,28 evaluated the PFT’s of 25 patients with SLE 
serially over a period of 2 to 7 years. Reduction in diffusing capacity, 
FVC, and TLC did not change significantly with time. In contrast, small 
airway function decreased significantly with time and appeared not to be 
related to smoking history. The significance of this finding is not clear, 
however, in view of the finding by Andronopoulos et al27, that the 
prevalence of small airway  disease in patients with SLE is same as that 
in healthy controls. In the absence of respiratory symptoms, isolated 
abnormalities in PFT such as a reduced DLCO do not require treatment 
but should be monitored, and further  investigation with HRCT chest 
scanning should be considered.       
HIGH RESOLUTION COMPUTED TOMOGRAPHY (HRCT) 
High resolution CT (HRCT) is an essential tool in the evaluation of 
lung  disease in SLE. Early inflammatory lesion may be visualized as 
 19 
alveolar or ground glass shadowing, and later in the disease course 
fibrotic lesions  may be visible as fixed reticular honeycombing. These 
finding of late inspiratory  crackles at the lung bases. 
            The radiographic findings is acute lupus  pneumonitis  consist of 
patchy  unilateral or bilateral areas of ground –glass opacity or air-space 
consolidation , often associated with pleural effusions. 
Alveolar hemorrhage is manifested radio logically by bilateral, 
patchy,  ill-defined areas of consolidation involving mainly the lower 
lung zones.  Radiographic evidence of interstitial fibrosis is seen in a 
small percentage  of patients who have SLE. It was reported in 3 or 28 
patients in one  series29. 
          Horizontal lines shadows are seen relatively common in patients 
who have SLE. They are usually present in the lung bases, are usually 
migratory, and are attributable to subsegmental atelectasis. Cavitary 
pulmonary nodules are rare. The lesion can be as a result of infection or 
infarction. 
In a prospective study of 48 patients who had serologically 
confirmed disease but no prior clinical evidence of pulmonary 
involvement, chest radiographs demonstrated evidence of fibrosis in 6% 
and were normal in 94%30 . Of these who had normal radiographs, 38% 
had  abnormal findings on HRCT. The most common abnormalities were 
interlobular  septal  thickening, intralobular interstitial thickening, small 
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rounded  areas of consolidation and areas of ground-glass attenuation. 
The abnormalities occurred mainly in the lower lobes. The fibrosis 
involved mainly the subpleural  lung regions. 
In another prospective study, 34 patients who had SLE were 
assessed using  chest radiography, HRCT, and pulmonary function tests31. 
The plain chest radiograph was abnormal in  8 patients (24%), Pulmonary 
function abnormalities were present in 14 (41%), and HRCT 
abnormalities were identified in 24 (70%). The authors reported that 11 
patients (32%) had definite evidence of interstitial lung disease, which 
was mild in 5 patients and moderately advanced in 6. Nine of the 11 
patients who had evidence of interstitial lung disease on HRCT were 
asymptomatic, 7 had normal chest radiographs, and 4 had normal 
pulmonary function tests. Airway disease-defined  as bronchial dilation or 
bronchial wall thickening-was observed in 12 patients (9 of whom had 
never smoked  cigarettes). 
As might be expected, the prevalence of parenchymal  
abnormalities is highest in patients who have long standing SLE and 
chronic respiratory symptoms . In one study of 10 patients who had mean 
duration of SLE of 7.5% years and who had respiratory symptoms for a 
mean of 2.5 years, all patients had  abnormal  pulmonary  function tests 
and  HRCT scans  (4 had normal chest radiographs)32 . The most common 
abnormalities on HRCT were areas of ground glass attenuation (seen in 8 
patients), honeycombing (in 7), and pleural thickening (in 8). Two 
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patients had airway abnormalities, consisting of bronchial dilation in one 
and centrilobular nodular and branching linear opacities (“tree in bud” 
appearance)  in the other. 
NUCLEAR MEDICINE IMAGING 
Ventilation Perfusion (VIQ) Scans 
In any patient with SLE presenting with breathless and pleuritic 
pains, the possibility of pulmonary embolism should be considered. V/Q 
scans offer a simple and reasonably reliable screening test for pulmonary 
embolism that can be used with CT pulmonary angiography where the 
results are indeterminate .V/Q scans may also be abnormal in the absence 
of pulmonary embolism, and severe pulmonary hypertension may 
produce an appearance of  hypoperfusion   in the peripheral areas of the 
lung. The combined use of D-dimer assays, V/Q scanning, and where the 
appropriate, CT pulmonary angiography may raise the accuracy in 
diagnosing pulmonary  embolism33 Gallium-67 scans have been useful in 
the diagnosis and monitoring of patients  with sarcoidosis, but there is 
little data on their use in the assessment of pulmonary disease in the 
lupus.  
Witt et al.34 studied lupus patients with interstitial lung disease and 
found an association between the presence of late inspiratory crackles 
clinically and increased uptake on Gallium–67 scanning and abnormal 
broncho alveolar  lavage. However, abnormal Gallium–67 scans were 
 22 
seen in only 37% of SLE patients compared to a prevalence of 74% with 
late inspiratory crackles and 95% of patients with abnormal CT chests, 
making the scans somewhat insensitive at picking up interstitial lung 
disease. 
ARTERIAL BLOOD GASES 
Arterial blood gases give an accurate estimate of alveolar 
ventilation .It is essential in the assessment of pulmonary embolism, 
extensive pulmonary infiltration, severe pneumonia, pulmonary 
hemorrhage, and acute reversible hypoxemia where (type I respiratory 
failure) may occur. 
BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE (BAL) 
These techniques may be useful when evaluating the etiology of 
interstitial pulmonary shadowing in patients with lupus. BAL fluid may 
be examined to exclude opportunistic infections especially in immuno 
suppressed patients. In patients with suspected interstitial lung disease 
where CT chest images show ground–glass shadowing with a honey 
comb appearance, elevated cell counts in BAL fluid may suggest alveolar 
inflammation and direct treatment with immunosuppressive agents once 
infection has been excluded. 
The technique of BAL facilitates the analysis of cellular and 
soluble   components from the epithelial surface of the lower respiratory 
tract. BAL has yielded valuable information about immune responses and 
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the pathogenesis of lung injury in the connective tissue diseases, 
especially Systemic sclerosis and Rheumatoid arthritis (RA) .BAL 
findings may be diagnostic in some diseases, such as infections; in others, 
however, findings are nonspecific but may contribute to the management 
of these diseases. For example, an increased of BAL eosinophils were 
associated with progressive lung disease in Idiopathic Interstitial 
pulmonary fibrosis, and  Scleroderma35. 
 In a multicenter study designed to standardize the test procedure, 
BAL was performed in 24 patients with diffuse ILD, secondary to 
rheumatic disorders, including SLE36. The total number of cells in the 
BAL fluid was increased with the percentage increase in neutrophils and 
decrease in macrophages. Total protein, Immunoglobulin M (IgM), IgG, 
and IgA, but not albumin, increased in concentration in the BAL fluid. 
Wataert et al.37 studied BAL fluid in 61 patients with collagen vascular 
disease without symptoms, and included in their study were 11 patients 
with SLE, all of whom had normal  PFT results. An abnormal differential 
count of BAL fluid leukocytes was found in 48 of patients, including 
three with SLE .In contrast to patients with RA and systemic sclerosis, 
who had a predominant polymorphonuclear alveolitis, patients with SLE 
showed a lymphocytic predominance. An increased percentage of BAL 
fluid eosinophils was also found in two patients with SLE and ILD35. 
Similarly, Witt et al34 found elevated lymphocyte and  neutrophil  counts 
in the BAL fluid from 19 lupus patients. 
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Alveolar macrophages in BAL fluid from 17 patients with inactive 
SLE were found to be normal in number, viability, and respiratory burst 
activity, but had severely impaired antibacterial function37. This 
dysfunction, which was observed in both steroid –treated and untreated 
patients, may contribute to the increased frequency of pulmonary 
infections in this disease. 
Wataert et al.38 introduced the concept of subclinical alveolitis in 
SLE and in other systemic rheumatic diseases, which is characterized by 
the accumulation of inflammatory and immune cells in the BAL fluid of 
patients without respiratory with a normal chest radiograph, and with or 
without significant PFT abnormalities. The clinical significance of 
subclinical  alveolitis, however is not clear since it is not known  how 
many of these  patients  will develop overt interstitial  lung disease. 
Higher concentrations of soluble immune complexes have been 
observed in BAL fluid compared to the corresponding serum specimen  
from patients with ILD associated  with rheumatic diseases, including 
SLE39 .Immune complexes were also seen within the cytoplasm of BAL  
neutrophils ,indicating  that locally formed immune complexes may 
induce an inflammatory response in the lungs of these patients. 
Increased numbers of activated CD8: T lymphocytes and natural 
killer (NK) cells were found in the BAL fluid of lupus patients with 
abnormal  Pulmonary function tests and correlated  with reduced carbon 
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monoxide transfer factor  and diffusing capacity values40. In contrast the 
number of CD19+ B cells in the BAL fluid was lower than that seen in 
the fluid of healthy controls, despite the high percentage of these cells in 
SLE peripheral blood .The observations suggest a cell-mediated immune 
response in the lungs in SLE40. 
BAL, therefore may be a potentially useful technique in the 
assessment and follow –up of patients with SLE and pulmonary 
involvement, especially in those with acute lupus pneumonitis and 
chronic diffuse ILD. 
CLINICAL MANIFESTATIONS OF PULMONARY 
INVOLVEMENT IN LUPUS 
Respiratory tract involvement occurs in about half of the lupus 
patients over their disease course. The following sections describe the 
main features of lung disease in SLE. 
           The various pulmonary manifestations  are classified as follows: 
PLEURAL DISEASE   
♦ Pleuritis with and without effusion. 
PARENCHYMAL DISEASE 
♦ Acute lupus pneumonitis  
♦ Interstitial pneumonitis and fibrosis  
♦ Pulmonary hemorrhage 
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VASCULAR DISEASE 
♦ Pulmonary artery thrombosis 
♦ Pulmonary thromboembolism 
♦ Pulmonary hypertension 
AIRWAY DISEASE 
♦ Obliterative  Bronchiolitis 
♦ Bronchiolitis obliterans organizing pneumonia 
NEUROMUSCULAR DISEASE 
♦ Diaphragmatic dysfunction 
THE PLEURA IN SLE 
Pleurisy   
Pleurisy is the most common manifestations of pulmonary 
involvement in SLE, and the pleura is involved more commonly in lupus 
than in any other connective tissue disease. Several early studies 
documented the prevalence of pleural involvement. For example, in 
Dubois and Tuffanelli’s41 520 patients, the cumulative incidence of 
recurrent pleuritic pain was 45% and that of pleural effusions was 30%. 
McGehee Harvey et al.42 reported pleurisy in 56% of their patients with   
recurrent  pleuritic  episodes in 13% , while 16% had associated pleural 
effusions . 
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 Several other studies have documented high prevalences of 
pleuritis, ranging  from 41% to 56% 19,43, being found more commonly in 
blacks than whites44. Perhaps the largest study to date, that of 1000 
European lupus patients, found a prevalence at disease onset of serositis 
(including) both pleural and pericardial inflammation) of 17% with a 
cumulative  incidence of 36% ,with pleuritis occurring  more commonly 
in men than in women45. Lung involvement defined as acute or chronic 
lupus pneumonitis was much less common, with a prevalence at disease 
onset of 3% and cumulative incidence of 7%-almost certainly an 
underestimate. The highest prevalence comes from a postmortem study:  
Ropes46 described pleural changes in 93% of 58 patients with SLE 
at autopsy, with fluid in the pleural cavity in 33 cases. 
CLINICAL FEATURES 
Pleurisy as the initial manifestations of SLE was noted by Dubois47 
in 13 of 520 patients. Pleuritic symptoms may antedate other 
manifestations of lupus by months or even years, resulting in a delay in 
the diagnosis of SLE48. 
Pleuritic chest pain may be unilateral or bilateral, and is usually 
located at the costophrenic margins, either anteriorly or posteriorly. 
Attacks of pleuritic pain often last for several days, and when associated 
with effusions, the pain may persist for weeks often accompanied by 
cough, dyspnea, or fever. The effusion generally occurs on the side of the 
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chest pain. Pleural effusions may also occur in patients with SLE and 
nephrotic Syndrome; infections such as tuberculosis; or cardiac failure18. 
Massive bilateral pleural effusion is a rare presenting feature of the 
disease49. It is important to remember that the differential diagnosis of 
pleuritic pain in a patient with lupus may include infection and 
pulmonary embolism, especially in the presence of antiphospholipid 
antibodies. 
PLEURAL FLUID  
The volume of pleural effusions usually is small to moderate (400 
to 1000 ml) and may be unilateral or bilateral. Large pleural effusions are 
uncommon9,50. Thoracocentesis is not always necessary in lupus patients 
unless the cause of the pleural effusion is uncertain and infection is 
suspected. The pleural fluid is SLE is usually exudative in character, 
although transudates have also been reported9. The fluid can be yellow, 
amber, or slightly turbid in color. In a study of 14 patients with lupus  
pleuritis50, the white cell count in the pleural  fluids ranged from 325 to 
14,950 cells/ml (mean 4,895 cells/ML). Half the specimens showed a 
predominance of polymorphonuclear leukocytes, with cell counts ranging 
from 10% to 100% (mean, 57%). Kelley et al.51 examined pleural 
effusions from ten patients with SLE and found atypical cells resembling 
plasma cells. The presence of these cells with other inflammatory cells, 
fibrinoid debris, erythrocytes and few mesothelial cells and in the absence 
of pathogenic organisms or malignant cells constituted a pattern that was 
characteristic of SLE in eight of the ten patients studied. 
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In most patients with lupus pleuritis, the pleural fluid glucose 
concentration is greater than 60 mg/dl, with a pleural  fluid/serum glucose 
ratio of greater than 0.5. Good et al.50 found the mean pleural fluid /serum 
glucose ratio to be 0.3 or lower. This contrasts with the findings of low 
glucose levels in the pleural fluids of patients with RA and pleurisy, in 
whom the glucose concentration is less than 30 mg/dl in 75% of 
patients52. Low glucose concentration, or a low pleural fluid/serum 
glucose ratio, may also occur in those with malignant effusions,  
empyema, or  tuberculosis52 . The pH of SLE pleural fluid usually is 
greater than 7.35. A few patients have a pH of less than 7.3%, which  is 
associated  with a low pleural  fluid glucose level 50,52. 
Classic LE cells have been documented in smears of pleural fluids 
from patients with SLE 50,53,54. It has been suggested that the presence of 
in vivo LE cells in the pleural fluid is highly characteristic with SLE55. 
However, the LE  cell test is now largely obsolete and has been replaced 
by searching for antinuclear antibodies (ANAs) in pleural fluid11. 
The presence of ANA’s in the pleural fluid may be a useful 
diagnostic test for patients with undiagnosed pleural effusions. For 
instance, Leechawengwong et al.56 tested pleural fluid from 100 
consecutive  patients  with  pleural effusion  and found positive  ANA  in 
all seven patients with  SLE and in one patient  with  drug induced   LE, 
but not in patients with  other diagnosis. Conversely, Small et al.57 found 
that a positive  ANA in the pleural fluid  was not  specific for SLE ; it 
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also  was found  in patients  without SLE but with pleural effusions who 
tested positive for  ANA in the blood.  Khare et al.58 found positive ANA 
in eight of 74  non–lupus pleural effusions (10.8%), including  those 
associated  with malignancy. 
Good et al.50 measured the ANA titer in paired samples of pleural 
fluid  and serum  of patients  with SLE .In lupus  pleuritis , the pleural 
fluid/serum ANA ratio was greater than 1. In contrast the ratio with less 
than 1 in patients with SLE who had pleural effusions from other causes, 
such as congestive heart failure. Moreover, none of 67 patients with 
pleural  effusions  of different causes had a positive ANA. 
ACUTE LUPUS PNEUMONITIS 
Acute lupus pneumonitis is an uncommon clinical manifestation of 
SLE. Patients with acute lupus pneumonitis usually present with fever, 
dyspnoea, cough productive of scanty sputum, hemoptysis, tachypnea, 
and pleuritic chest pain59 physical finding commonly include basal 
crepitations, and, when severe central cyanosis may be present. 
In Estes and Christians43 series of 150 patients, 48% had evidence 
of pulmonary involvement at sometime during the course of their illness, 
but only 14 (9%) had acute lupus pneumonitis. 
Acute lupus pneumonitis carries a poor prognosis. Of 12 patients 
reported by Matthay et al.,59 the mortality was 50% during the acute 
 31 
episode from respiratory failure, opportunistic infection and 
thromboembolism. All six surviving patients remained relatively well 
after more than a year follow–up, but three developed residual interstitial 
infiltrates with abnormal pulmonary function tests, indicating the acute 
process can progress to chronic interstitial lung disease. Adult respiratory 
distress syndrome (ARDS) may occur with acute lupus pneumonitis, 
greatly increases the risk of mortality. 
PULMONARY HEMORRHAGE 
Pulmonary hemorrhage is a rare, devastating, and frequently fatal 
manifestation of SLE with mortality rates of 70% to 90%. Frank 
hemoptysis does not always occur, even with massive intra-alveolar 
hemorrhage, so the clinical diagnosis is often delayed. For example, in a 
series of 140 patients with SLE, three developed pulmonary hemorrhage, 
and in two of these patients the diagnosis was made only at autopsy60. 
The triad of anemia, air space consolidation and hemoptysis should 
suggest the possibility of diffuse alveolar haemorrhage. Anemia with a 
dropping hematocrit in the face of worsening radiologic abnormalities is 
characteristic. Many patients have concomitant lupus nephritis. With 
cessation of bleeding, radiographic and clinical improvement is rapid. 
The morality rate has generally been reported to be in excess of 50%60. 
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CHRONIC DIFFUSE INTERSTITIAL LUNG DISEASE 
Diffuse ILD is a well recognized pulmonary manifestation of 
systemic rheumatic diseases. Particularly systemic sclerosis, 
Dermatomyositis, and Rheumatoid arthritis. The initial presentation of 
diffuse ILD in SLE can be one of the two types. The more common is an 
insidious onset of a chronic nonproductive cough, dyspnea on exertion, 
and history of recurrent pleuritic chest pain. Less commonly, ILD may 
develop in a patient following acute lupus pneumonitis: two studies 
suggest that  between 43% and  50% of patients with  acute  lupus 
pneumonitis  may go on  to  develop chronic diffuse ILD. 
ILD can occur at any time during the courser of SLE, but most 
cases develop in those with long-standing disease. Most patients have 
multisystem involvement and test positive for both ANA and anti–DNA 
antibodies. 
In the study by Eisenberg et al.,61, the mean age of their 18 patients 
with  SLE and ILD was 45.7 years, with a mean disease duration of 10.3 
years. Pulmonary manifestations were present for a mean of 6 years. 
Initially, 7 patients presented with pulmonary symptoms .All had 
dyspnoea on exertion, and 3 were  dyspnoeic, even at rest.12 complained 
of cough with scanty sputum ,and a similar number had pleuritic chest 
pain. All patients had poor diaphragmatic movement, with diminished 
resonance to percussion over the lung bases. Cyanosis and clubbing was 
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present in 1 patients, and 12 had basilar rales. All 18 had persistent, 
diffuse interstitial infiltrates on chest radiography. A pleural reaction was 
present in 9 patients and plate like atelectasis in 6.  
HIGH RESOLUTION CT SCANS IN INTERSTITIAL LUNG 
DISEASE 
High-resolution CT scans (HRCT) of the lungs have been reported 
to be promising in the diagnosis, assessment of disease activity in the 
diagnosis, assessment of disease activity in the lung parenchyma, and a 
providing prognostic information in ILD. 
Johkoh et al.,62 compared HRCT lung scans and pulmonary 
functions tests in idiopathic pulmonary fibrosis and ILD associated with 
SLE. The extent of morphologic changes that were observed correlated 
with severity of impairment of diffusing capacity in both groups. The 
effectiveness of  corticosteroids for treatment was reasonably predicted. 
Steriod-responsive patients showed a ground glass and alveolar 
consolidation and no honeycomb lesions on the HRCT scans. On the 
other hand, patients who failed to respond to therapy had severe honey 
comb lesions on the HRCT scans. 
PULMONARY EMBOLISM 
Pleuritic chest pain and dyspnea are relatively common, and most 
patients with SLE presenting with these symptoms usually have pleurisy  
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or pneumonitis. However, pulmonary embolism (PE) should always be 
considered especially if antiphospholipid antibodies are present or there is 
a previous history of PE. The predictive value of V/Q scans, D-dimer 
levels, and CT pulmonary angiography has been discussed above and it 
should be remembered that abnormal perfusion scans may occur in 
patients with active  lung disease in the absence of PE. Nevertheless, if 
PE is suspected clinically in a patient with a low probability V/Q scan, 
angiography should be performed. 
Peripheral deep venous thrombosis  (DVT) is common in patients 
with SLE and predisposes to PE12,41,43,63. Perhaps the most widely 
recognized risk factor for venous thromboembolism in SLE in the 
presence of circulating lupus anticoagulants and other antiphospholipid  
antibodies64-66. In European study of 1000 patients, antiphospholipid 
antibodies including the lupus anticoagulants were significantly 
associated with thrombosis, fetal losses, thrombocytopenia, and livedo 
reticularis45. Patients who develop DVT and/or PE in the context of 
antiphospholipid antibodies will usually require lifelong 
anticoagulation67. 
PULMONARY HYPERTENSION 
Clinical presentation  
Severe symptomatic pulmonary hypertension (PHT) is a relatively 
rare manifestations of lung involvement in SLE, but mild subclinical 
cases are surprisingly common with  prevalences  5% and 14%. 
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Perez and Kramer71 were the first to report four patients with 
severe PHT in a group of 43 patients with SLE over a period of 2 years. 
Other studies, however found rather lower prevalences72. Of great interest 
in a five-year follow-up study of a cohort of lupus patients that showed 
that the prevalence of PHT rose from 14% to 43% with the mean 
pulmonary artery pressures rising from 23.4% mm Hg to 27.5mm Hg73. 
The clinical diagnosis of PHT is difficult to make in early and mild 
cases, and only the severe cases, with right ventricular hypertrophy and/or 
congestive heart failure, have been reported in the literature. Pulmonary 
artery pressure at rest and during exercise is significantly higher in 
unselected patients with SLE as compared to normal subjects, probably 
secondary to increased pulmonary vascular resistant in lupus patients74. A 
study of the prevalence and the severity of PHT in a group of 36 patients 
with SLE and healthy controls was undertaken by Simonson et al.75 using 
two dimensional and Doppler  echocardiographic  date to calculate 
pulmonary artery systole pressure. Five patients (14%) and none of the 
controls had PHT, as defined by a pulmonary artery pressure of greater 
than 30 mmHg. This study suggests that PHT is common in SLE, but 
usually mild in degree. Conceivably, mild cases of PHT in SLE may 
improve with systemic corticosteroid and/or cytotoxic drug therapy given 
for other organ involvement, so that mild PHT remains unrecognized. 
The symptoms of PHT in SLE are in general similar to those of 
patients with idiopathic or primary PHT72.  In most of the reported cases, 
the symptoms of PHT occurred within a few years of onset of the 
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multisystem disease, with a mean duration of approximately 2.3 years72. 
The most common complaints are dyspnea on exertion, chest pain, and 
chronic nonproductive cough. Chronic fatigue, weakness, palpitations, 
edema, and /or ascites may also occur. Symptoms usually develop 
insidiously and progress gradually. The physical findings may include a 
loud second pulmonary heart sound, systolic murmur, and right 
ventricular lift. Chest radiography findings include cardiomegaly with a 
prominent pulmonary artery and clear lung fields. Electrocardiography 
may show changes of right ventricular hypertrophy. Although PFTs may 
show restrictive abnormalities, these are mild in degree and 
disproportionate to the severity of the PHT. Pulmonary  angiograms  in 
severe cases  demonstrate symmetric dilation of the central pulmonary 
artery trunk, with  pruning of the peripheral  blood vessels. Cardiac 
catheterization is the definitive investigation and demonstrates the 
characteristic elevation of the pulmonary artery pressure and normal 
wedge pressure with out evidence of intracardiac or extracardiac 
shunting. 
REVERSIBLE HYPOXEMIA 
A relatively rare syndrome of acute reversible hypoxemia in 
acutely ill patients with SLE but without evidence of parenchymal lung 
involvement may occur68-70. The first description was b y Abramson et 
al.68. 
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Among 22 inpatients with acute disease exacerbation, six  (27%) 
had this syndrome. Although some patients had mild pleuropulmonary 
symptoms, chest  radiographs and lung scans were normal. The patients 
had hypoxemia and hypocapnia with a wide alveolar-arterial  (A-a) 
gradient, which reversed with corticosteroid therapy. The pathogenesis of 
the syndrome is unclear, but a correlation between hypoxemia and the 
level of complement split products was noted, and others have suggested 
a relationship with disease activity69. Complement activation may lead to 
diffuse pulmonary injury with the aggregation of neutrophils in the lungs 
similar to that seen in cardiopulmonary bypass, hemodialysis with 
cuprophane membranes, and ARDS.      
SHRINKING LUNG SYNDROME 
In 1965, Hoffbrand Beck76 described a group of patients with SLE 
with breathlessness and reduce chest expansion, but no cyanosis, 
clubbing, or abnormal auscultatory findings. Many of the patients had a 
previous history of pleurisy. Chest radiography revealed clear lung fields 
but with an elevated diaphragm, which moved sluggishly and 
paradoxically .The vital capacity was extremely reduced. 
The authors coined the term shrinking lung syndrome and 
suggested that the main pathologic lesion is that of alveolar atelectasis 
secondary to deficiency of the surface tension reducing film that lines the 
normal alveoli. Gibson patients by determining the transdiaphragmatic 
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pressure using a double-balloon technique, and they found it to be grossly 
abnormal. This finding led them to suggest that diaphragmatic 
dysfunction, rather than parenchymal or pleural disease, accounts for the 
unexplained dyspnea in these patients. Martens et al.78 concluded that the 
restrictive ventilatory defect in these patients results primarily from the 
weakness of expiratory and inspiratory muscles.  
Diaphragmatic dysfunction correlated with the degree of dyspnea 
but not with overall disease activity, proximal muscle weakness, or 
serologic markers. Contrary to these reports, however, Laroche et al.79, 
using a wide range of tests for determining respiratory muscle strength, 
found no evidence of isolated weakness of the diaphragm in 12 patients 
with SLE and this syndrome. The discrepancy between their results and 
those of previous studies is not entirely clear, but it may result partly from 
patient selection and differences in the methods that were used to assess 
diaphragmatic function. 
The pathogenesis of the diaphragmatic weakness in patients with 
SLE is not well understood. Wilcox et al.80 found no evidence of phrenic 
nerve neuropathy as the cause of this weakness. Diffuse fibrosis of the 
diaphragm without evidence of acute inflammatory infiltrates was 
observed in one patient examined at autopsy81, supporting an 
extrapulmonary, restrictive cause for this unusual syndrome. 
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An electromyographic study of the diaphragm and external 
intercostal  muscles demonstrated  that fatigue  of the respiratory muscles  
occurs at lower loads in patients with SLE as compared  to those in 
healthy controls81.Whether myopathy  is an isolated process affecting 
primarily the diaphragm and other respiratory muscles or is part of a 
generalized  muscle disease in SLE is not entirely clear. When the 
diagnosis of shrinking lung syndrome is suspected, measurements of 
transdiaphragmatic pressures and elastic recoil of the respiratory  system 
should be considered. 
The clinical course of the syndrome is a chronic, low grade 
restrictive defect. Follow –up of some patients over a period of several 
years has shown that the volume restriction is not progressive77,78. In 
symptomatic patients,  prednisone therapy (30 to 60 mg  daily for several  
weeks) is  clinically beneficial  and  tends to stabilize the PFT 
abnormalities83-85. Agonist agents and theophylline  may also be useful  in 
the treatment  of this syndrome86,87. 
AIRWAY OBSTRUCTION 
Severe airway obstruction has been reported in a small number of 
patients with SLE88,89. Lung biopsy in one patient showed obliterative 
bronchiolitis and an acute inflammatory process that affected small 
bronchi and bronchioles, resulting in necrosis and eventual endobronchial 
proliferation of epithelial cells and peribronchial infiltration by 
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lymphocytes. Dense plugs composed of alveolar debris and fibrin strands 
within the bronchioles caused partial or complete obstruction. 
Bronchiolitis obliterans with organizing pneumonia has been described in 
SLE90. 
Evidence of airway obstruction has been described in several 
controlled studies of PFT in patients with SLE91-94. Some series did not 
take into consideration the effect of cigarette smoking, but in those that 
did it was evident that airway obstruction occurred even in nonsmoking 
patients with SLE. The frequency of airway obstruction is variable, 
primarily because of differences in the criteria that are used to define the 
abnormality and in the selection of patients. 
In the only controlled study of lifelong nonsmoking patients with 
SLE, Andonopoulos et al.27 observed a high prevalence (24%) of isolated 
small airway  disease in patients  with SLE. 
The clinical significance of this observation remains unclear, 
however, because a similarly high frequency  (17%) of small airway 
disease was found in their healthy, non smoking age-and sex –matched 
controls. 
         Very occasionally the upper airways have been affected in lupus. 
Case reports have described hypopharyngeal ulceration, laryngeal 
inflammation, vocal cord paralysis, epiglottitis and subglottic stenosis. 
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MATERIALS AND METHODS 
Data for the study were collected  from patients diagnosed to have 
SLE and attending regular follow up at the Department of  
Rheumatology, and at the Institute of Internal Medicine, Madras Medical 
College and Research   Institute, Chennai. The above patients were 
investigated for Pulmonary abnormalities at the Department of 
Rheumatology and the Institute of Internal Medicine. Serological 
investigations were done at the Immunology Department. Pulmonary 
Function testing was done at Institute of Internal Medicine. High 
resolution Computed tomography was carried out in the Barnard Institute 
of Radiation and Oncology (BIRO), Madras Medical College.  
STUDY PERIOD 
The study was conducted during the period Feb 2005 to Feb 2006. 
Thirty SLE patients were enrolled for the study after satisfying inclusion 
and exclusion criteria. After enrollment, the patients were evaluated for 
the presence of pulmonary abnormalities. 
STUDY DESIGN 
To evaluate the pulmonary profile in patients with SLE, 
prospective study design was chosen. The cases were selected based on 
inclusion and exclusion criteria. 
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CASE IDENTIFICATION AND VALIDATION 
          Patients who were diagnosed to have SLE and were attending the 
Department of Rheumatology and the Institute of Internal Medicine for 
regular follow up during the period Feb 2005–Feb 2006 were examined 
and the possibility of inclusion in our study and evaluated. 
Patients were diagnosed as having SLE based on the American 
College of  Rheumatology (ACR) criteria. 
1. Malar Rash 
2. Discoid Rash 
3. Photosensitivity 
4. Oral ulcers 
5. Arthritis 
6.  Serositis 
7. Renal Disorder 
8. Neurologic Disorder 
9. Hematologic Disorder 
10. Immunologic Disorder 
11. Antinuclear Antibodies(ANA) 
If four of these criteria are present at any time during the course of 
disease, a diagnosis of Systemic Lupus can be made. 
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INCLUSION CRITERIA 
A patient with SLE diagnosed on the basis of the American 
College of Rheumatology (ACR) criteria. 
EXCLUSION CRITERIA 
The following patients were excluded from the study. 
1. Smokers 
2. COPD  
3. Pulmonary  Tuberculosis(PT)  
4. Bronchial asthma  
5. Chronic Lung disease  
6. Patients with exposure to dusts  
The patients were questioned about the duration of the disease and 
enquired whether they had symptoms of respiratory disease or not. They 
were then divided into symptomatic patients.  
Among the symptomatic patients, a questionnaire were prepared to 
extract details about respiratory complaints .The duration of symptoms 
namely  cough, breathlessness, chest pain,  hemoptysis were noted . 
The patients were asked whether they developed the symptoms 
before or after the diagnosis of SLE. If pulmonary symptoms were 
present before the diagnosis of SLE, then the cases were excluded. Also if 
 44 
patients had chest pain, breathlessness of cardiac origin, they were 
excluded from the study. 
Patients with history of smoking, chronic obstructive pulmonary 
Disease (COPD), Previous history of Pulmonary Tuberculosis, Bronchial 
Asthma and Chronic lung disease were excluded. Also patients with 
occupational exposure to dusts were excluded. 
Patients with history of smoking, chronic obstructive pulmonary 
Disease (COPD), Previous history of Pulmonary Tuberculosis, Bronchial 
Asthma and Chronic lung disease were excluded. Also patients with 
occupational exposure to dusts were excluded. 
EVALUATION OF CASES 
Patients who were included in the study were admitted in the 
Medical/ Rheumatology wards and through physical examinations was 
carried out to disclose respiratory findings. After clinical exam, the 
patients underwent laboratory investigation like complete hemogram,  
renal parameters, etc.   
Preliminary imaging was done with chest skiagram, Serological 
testing included anti nuclear antibody (ANA), double Stranded DNA(ds 
DNA) anti Sm antibody, for all patients. 
Then the patients were subjected to subsequent radiological 
imaging with High Resolution CT and Pulmonary Function Testing. 
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TECHNIQUE OF HIGH RESOLUTION TOMOGRAPHY  
CT is based on the principle that the internal structure of an object 
can be reconstructed from multiple projections of it. The CT image is a  
two– dimensional representation  of  a  three-dimensional  cross –
selectional slice, the third dimension being the section or slice thickness. 
The CT image is composed of multiple picture elements known as pixels. 
A pixel is a unit area, ie, each square on the image matrix, it 
reflects the attention of a unit volume of tissue or voxel, that corresponds 
to the area of the pixel multiplied by the scan collimation. The x-ray 
attention of the structures within a given voxel are averaged to produce a 
image. This volume averaging results in loss of spatial resolution, the 
thicker the slice, the lower the ability of CT to resolve small structure. 
Slice thickness can be varied to provide optimal assessment. For instance, 
in the evaluation of fine parenchymal detail such as interlobular septa, 
thin sections (1-2mm) are superior to thicker sections (7-10mm). More 
over, as section thickness increase noise increases and gainer images 
result31 . 
A conventional CT scan of the chest consists of a series of 
individual cross-sectional slices obtained during suspended respiration. 
After each slice is obtained, the patient is allowed to breath while the 
table is moved to the next scanning position. This method of obtaining a 
series of individual cross–sectional images is known as incremental CT 
scanning. 
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Spiral (Helical) CT is a major technical advance that allows 
continuous scanning while the patient is continuously moved through the 
gantry. The continuous nature of the data acquisition allows true 
volumetric scanning and the production of multiple over lapping images 
that result in increased spatial resolution in the longitudinal axis. 
 In the majority of the cases, the CT scan data are reconstructed by 
using a standard or soft tissue algorithm that smooth the image and 
reduces visible image noise. This reconstruction algorithm is preferred in 
the assessment of abnormalities of the mediastinum and chest wall. It 
reduces image soothing and increases spatial resolution, thereby allowing 
better visualization of small abnormalities. The combination of thin 
section CT (1-2mm) and a high spatial frequency reconstruction 
algorithm provides for the optimal assessment of interstitial and air space 
lung disease and is referred to High Resolution CT (HRCT). 
The main indications for the use of HRCT (1-2mm, high –spatial 
frequency reconstruction algorithm) include: 
1. Diagnosis of Bronchiectasis 
2. Detection of Parenchymal Lung Disease. Patients with 
symptoms or  pulmonary function abnormalities suggestive 
of parenchymal lung disease but normal or questionable 
radiographic findings can be  assessed. 
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3. Differential Diagnosis of Diffuse lung disease HRCT can be 
used to assess patients in whom the combination of clinical 
and radiographic findings does not provide a confident 
diagnosis and further radiographic assessment is considered 
warranted. This indication in  particular include patients with 
chronic interstitial and air space disease and immune 
comprised patients with acute parenchymal abnormalities, in 
such patients the different diagnosis can be narrowed  or a 
specific diagnosis often made on HRCT even when the  
radiographic findings are non specific. 
PULMONARY FUNCTION TESTS 
The clinical significance of pulmonary function test has been 
established exemplifying the statement of sterling “the physiology of 
today is the medicine of tomorrow”. The pulmonary function tests 
(PFTs). 
1. Give an objective evidence of lung function that has been 
deranged by the disease process involving the bronchial tree 
and the lung, the pulmonary vasculature and the chest 
bellows. 
2. Help to execute a respiratory cause of breathlessness. 
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Flow-volume curves in different conditions:  O, obstructive disease; R(E) Extra 
parenchymal restrictive disease with limitation in both inspiration and  
expiration. Forced expiration is plotted in all conditions; forced inspiration is 
shown only for the normal curve, TLC, Total lung capacity; RV; Residual 
volume. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spirograpic tracings of forced expiration, comparing a normal tracing (A) and 
tracings in the obstructive (B) and Parenchymal restrictive (C) disease. 
Calculation of FVC, FEV1 and FEF25-75%  are shown only  for the normal tracing. 
Since there is no measure of absolute starting volume with the spirometry, the 
curves are  artificially positioned to show the relative starting  volume in 
different conditions. 
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Lung volumes, shown by block diagrams (left)and  spirograpic tracing (right). 
TLC : Total lung capacity, VC : Vital capacity, RV :  Residual volume 
IC: Inspiratory capacity, ERV  : Expiratory reserve volume, 
FRC: Functional residual capacity, VT : Tidal volume 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
             
 
 
 
 
 
 
A. Pressure-volume curve of  the lungs, B.  Pressure-volume curve of the chest 
wall, C. Pressure-volume curve of the respiratory system, showing superimposed 
component curves of the lungs and the chest wall. RV: Residual volume, 
FRC : Functional residual capacity, TLC:  Total lung capacity 
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3. Help in the assessment of the course of a disease overtime 
such as COPD. 
4. Help in differentiating the types of respiratory failure and 
5. Detect airway responsiveness. 
THE SPIROMETER   
Volume changes of the lung are usually measured at the mouth, 
preferably by means of a spirometer or else in pneumotachograph and 
integrator. The types of spirometer are 
1. Closed system and 
2. Open system, which uses a differential pressure transducer. 
The spirometer should be capable of recording the full vital 
capacity as a function of time. The minimal driving pressure, ie the 
minimum pressure at the mouth that causes volume deflection, should be 
0.03kPa. 
THE TECHNIQUE 
The technician is required to calibrate the spirometer to a given 
standard, daily, before subjecting any patient to a spirometric test. Each 
patient’s anthropometric data in terms of race, sex, age, height and weight 
is entered in the computer. The machine is corrected for ambient 
temperature and pressure. 
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The patient is then connected to the spirometer tubing using a 
mouthpiece and all leaks around the mouthpiece are seen to be occluded. 
Nasal leaks are prevented by occluding the nose with nasal clips. The 
patient is then asked to breath normally in the spirometer circuit for a 
couple of breaths and then take a maximum inspiration and a maximum 
forceful expiration and continue till he cannot exhale any further and then 
again take an inspiration and stop. The computer then analyses these 
flows and volume in flow-volume and time-volume formats to give 
results, comparing them with the normal predicative values. 
STATIC LUNG VOLUMES AND CAPACITIES   
Pulmonary gas transport depends on the degree and speed with 
which the pulmonary gas volume can change23. 
Static lung volumes are measured by methods in which the velocity 
of the gas plays no part27. 
• The Total Lung Capacity (TLC) is the volume of gas contained 
in the lungs after maximum inspiration. 
• Residual Volume (RV) is the volume of gas remaining in the 
lungs at the end of maximum expiration. 
• The Vital Capacity (VC) is the volume of gas that is exhaled 
from lungs in going from TLC to RV. 
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• Functional Residual Capacity (FRC) is the volume of gas in the 
lungs at the end of normal expiration. 
DYNAMIC LUNG VOLUMES 
The measurements taken during fast breathing movements were 
described as dynamic volume changes. 
The forced expiratory volume in one second (FEV1), is the gas 
volume expired during the first second of a maximal forced expiration 
beginning  at the end of complete inspiration. 
The maximal voluntary ventilation (MVV) is the maximum 
volume of gas which can be expired per minute, the subject breathing at a 
frequency of 30 breaths per minute. 
PATTERNS OF ABNORMAL VENTILATORY CAPACITY 
In obstructive lung disease, the FEV1, is marked decreased, VC is 
decreased or normal, the ratio FEV1/FVC is decreased (<70%). 
In restrictive lung disease, FEV1 and VC are decreased and the 
Ratio FEV1/FVC is normal or increased. 
              Lung volumes and measurements made during forced expiration 
are interpreted by comparing the values measured with the values 
expected given the Age, Height, Sex and Race of the patient. Regression 
curves have been constructed on the basis of data obtained from large 
number of normal. 
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             Non-smoking individuals without evidence of lung disease. 
Predicted values for a given patient can then be obtained by using the 
patient’s age and height in the appropriate regression equation. Different 
equations are used depending on the patient’s age and gender because 
there is some variability among normal individuals, values between 80 
and 120% of predicted value have traditionally been considered normal. 
Increasingly, calculated percentiles are used in determining normality. 
Specifically, values of individual measurements falling below the fifth 
percentile are considered to be  below normal. The normal values of ratio 
FEV1/FVC is approximately 0.75 to 0.80, although this value does fall 
somewhat with advanced age. 
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RESULTS 
CLINICAL FINDINGS  
Among the thirty patients who were enrolled for the study, 27 were 
females and 3 were males (Female: Male ratio 9:1). The mean age was 26 
years, the youngest patient being 12 years and oldest patient being 53 
years. Patients had the disease for an average period of 3 years. The 
duration of respiratory symptoms varied from 1 month to 1 year, the 
average duration being 6 month. 
Out of the thirty Patients, 20 were symptomatic (66%). The 
predominant symptoms was breathlessness, which was present in 18 
patients (60%). Cough was the presenting complaint in 8 patients (30%). 
The other symptoms were fever, pleuritic chest pain, and generalized 
weakness. Clinical examination revealed abnormal findings in only 13 
patients (43%). 
Two patients, who were admitted with fever and cough had high 
pitched bronchial breath sounds bilaterally, suggesting the impression of 
pneumonitis (6%). Two patients had diminished intensity of breath 
sounds (6%). 
Nine patients had fine respiratory basal crepitations (30%). In the 
remaining 17 patients, clinical examination was normal. 
 55 
 
 
 
 
 
 
RADIOLOGIC IMAGING  
Chest Skiagram showed abnormal findings in 10 patients (33%). 
The commonest radiological pattern was bilateral haziness in both lower 
zones, which was present in 5 patients (16%). The haziness was 
homogenous, involved the lower zones. Consolidation pattern was seen in 
2 patients (6%). One patient had bilateral patchy opacities occupying both 
mid and lower zones. The other patient had a patchy opacity in the (R) 
lower zone. Both the patients had clinical features suggestive of 
pneumonitis. 
Cardiomegaly was present in one patient (3%), who also had 
prominence of pulmonary markings, raising the suspicion of pulmonary 
hypertension. 
Evidence of pleural effusion in the form of bilateral opacities of 
both lower zones with obliteration of costophrenic and cardiophrenic 
angle was seen in one patient (3%). 
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PULMONARY FUNCTION TEST REPORTS 
Among the 30 patients who underwent pulmonary function testing, 
26 patients showed abnormal pattern (86%). The pattern of abnormality 
was restrictive type in 17 patients (56%). The pattern was mildly 
restrictive in 4 (23%), moderately restrictive  in 4 (23%), and severe in 9 
patients (52%). The patients had reduction in forced expiratory volume in 
one second (FEV1), and Forced Vital Capacity (FVC) with normal or 
PATTERNS IN PFT
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elevated FEV1/FVC. A decrease in Residual Volume and Total Lung 
Capacity (TLC) was also evident. 
The staging of the restrictive pattern was made mainly on basis of 
these lung volumes, which were expressed in percentage of predicted 
normal after calibration with the units in terms of litres per minute. The 
volumes are normal if they were more than or equal to 80% of predicted 
normal, mild if 60-79%, moderate if 40-59%, and severe if less than 40%. 
Four patients (12%) had patterns suggesting air flow limitation, 
with reduced FEV, IFVC and normal or increased TLC, and elevated 
Residual Volume (RV). 
Five patients (16%) demonstrated combined restrictive obstructive 
impairment, showing decreased  forced vital capacity and expiratory flow  
rate. The total lung capacity was normal or low. 
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PERCENTAGE OF ABNORMALITIES IN X-RAY AND HRCT
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Fluid collection in the anterior ,posterior and lateral 
costophrenic recess , bilateral hemithroax . 
 
 
Left sided pleural effusion with chronic pleural thickening 
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Subpleural and interlobular septal thickening along with few 
subpleural cystic changes in bilateral lung fields along 
posterior costal aspects (prone ) 
 
Subpleural / interlobular septal thickening imparting irregular 
interphase along the pleural aspect. 
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Subpleural interstitial abnormality in the form of  
subpleural and interlobular septal thickening admist  
segmental ground glass opacity. 
 
End stage lung disease characterized by honeycombing  
and traction bronchiectasis in anterior and lateral basal  
segment of the left lower lobe. 
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Geographical pattern of air space opacities involving anterior and 
posterior segments of right upper lobe.the disease process is being 
limited posteriorly by the major fissure 
 
 
Bilateral fluid collection in the pleural space with  
loculation on the right side. 
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HIGH RESOLUTION CT 
• HRCT revealed abnormal findings in 16 patients (53%). It showed  
abnormalities even in patients who were asymptomatic  and 
clinically normal. 
• The commonest finding was that of bilateral ground glass 
homogenous shadows which were present in 8 patients (26%) the 
pattern was distributed mostly in the lower zones, the posterobasal 
segments being commonly affected. These radiologic abnormalities 
are seen in patients in the early stages of interstitial lung disease 
(ILD). 
• Four patients (12%) had consolidation changes with patchy 
homogenous opacities and air bronchogram. The distribution was 
bilateral in one patient and unilateral I in the other three patients. 
There was evidence of pleural effusion in the patient who had 
bilateral basal pneumonitis, and another patient had pleural 
thickening adjacent to the consolidation The changes were noted in 
the lower zones, the commonest segment being posterior basal. 
• Three patients (9%) had bilateral pleural effusion among which 2 
patients had mild haziness in the chest x-ray. 
• One patient (3%) had bilateral sub pleural reticulation, one of the 
early findings in ILD. 
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• There were diffuse micronodular opacities present bilaterally and 
scattered around the hilum in one patient (3%). 
• Findings indicative of pulmonary hypertension, namely prominent 
pulmonary vasculature, with cardiomegaly was seen in one patient 
(3%). 
• A bullous lesion was seen occupying the posterior basal segment of 
the left lower lobe in a patient who was symptomatically normal 
(3%). 
• And finally, a cavitary lesion with pleural thickening in the left 
lower lobe was demonstrated in a patient (3%). 
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DISCUSSION 
On analysing the results from the study, it is evident that 66% of 
the patients had respiratory abnormalities. 
Out of the 20 patients who had respiratory abnormality, the 
commonest one was that suggestive of early interstitial lung disease 
(ILD). This was evident from the ground glass shadows on HRCT, 
present in 8 patients (26%). 
Patients with features suggestive of early ILD presented with 
cough which was unproductive in nature and breathlessness. The 
symptoms had evolved about an average of 6 months since the diagnosis 
of SLE. In these patients, there was obvious clinical findings in only 30% 
.The diagnosis in the rest of the patients was made by HRCT. 
            Two patients presented with clinical picture of pneumonitis, 
which was unresponsive to antibiotics. Sputum examination did not 
reveal any micro organism. The patients were treated with antibodies for 
a long period of time without any improvement. Then, when the patients 
were referred to this hospital, the possibility of lupus pneumonitis was 
strongly considered and glucocorticoids were administered. The response 
were good and the general condition of the patients improved and the 
radiological findings also resolved. Thus, lupus pneumonitis should be 
considered in patients with SLE who present with pneumonitis 
unresponsive to antibiotics. 
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Pulmonary hypertension was the diagnosis in a patient who 
presented with progressive breathlessness. Imaging revealed prominence 
of pulmonary vasculature and cardiomegaly. The diagnosis was 
confirmed by echocardiogram. 
The duration of the disease strongly plays a role in the 
development of respiratory abnormalities. Patients who had longer 
duration of SLE presented with more pulmonary pathology than those in 
whom the disease was diagnosed recently. 
Clinically examination revealed abnormality in 13 patients. In 9 
patients, the clinical suspicion of ILD was made after excluding infection. 
In 2 patients, there was evidence of consolidation and in the other 2, there 
were findings suggestive of pleural effusion. 
Chest x-ray was normal in 10 patients (33%) and the commonest 
pattern being haziness involving both lower zones in 5 patients (15%). 
The other findings were pneumonitis in 2 patients (6%), prominence of 
pulmonary vessels in 1 (3%), pleural effusion in 1(3%), and cardiomegaly 
in 1(3%). 
Pulmonary function tests showed that 26 patients (86%) had 
abnormal patterns. Restrictive pattern was seen in 17 patients (56%), air 
flow limitation in 4(12%) and combined pattern in 5 (16%). 
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HRCT proved to be useful tool in identifying subtle anatomic 
changes in 16 patients (53%) had abnormal findings, the common pattern 
being ground glass pattern bilaterally in 8 patients (26%) the other pattern 
were consolidation in 4(12%), and bilateral pleural effusion in 1 (3%), 
subpleural reticulation in 1 (3%), cardiomegaly in 1 (3%), prominent 
pulmonary vessels in 1(3%) and micronodular changes in 1 (3%). Bullous 
lesion was evident in a patient who was asymptomatic and another patient 
had cavitary lesion without any previous pulmonary disease. 
In the study by Bankier et al..30 out of the 48 patients, chest 
radiographs were abnormal in 3 patients (6%) and HRCT was abnormal 
in 17(38%). The duration of SLE in this group of patients ranged from 8-
52 months. 
Fenlon et al.,31 showed in his study on 34 patients with SLE that 
chest x-ray was abnormal in 8 patients(24%), PFT in 14 (41%) and 
HRCT in 24(70%). 
Ooi GC, Ngan H.Peh WCG et al.,32 found that the prevalence of 
respiratory abnormality is highest in patients who have long  standing 
SLE and chronic respiratory symptoms. All patients had abnormal PFT 
and HRCT, the most common pattern in HRCT being ground glass 
appearance in 8 out of 10 patients and pleural thickening in eight. 
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In our study x-ray was abnormal in 10 patients (33%) PFT in 26 
patients (86%), and HRCT in 16 patients (53%). 33% of patients who 
were clinically normal showed abnormality in HRCT. 
Thus, with a sensitivity of 53% HRCT emerges as an invaluable 
non-invasive investigation in detecting pulmonary changes in SLE 
patients. 
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CONCLUSION 
• Respiratory abnormalities were present in 66% of patients with 
SLE. 
• The longer the duration of the disease, the more the likelihood 
of pulmonary pathology. 
• The commonest respiratory abnormality was found to be of 
early ILD, with ground glass pattern in HRCT. 
• HRCT evidence of ILD was frequently present despite absence 
of symptoms and normal chest radiograph. 
• Most patients had abnormalities in their PFT but did not 
demonstrate anatomically abnormality. Reduction in lung 
volumes was the most common finding, suggestive of  
restrictive patten of ILD. 
• HRCT was more sensitive in detecting anatomical abnormalities 
than any other non –invasive investigatory modality. 
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SUMMARY 
A Prospective study of respiratory abnormalities in systemic lupus 
erythematosus was done to correlate the clinical features with plain 
radiographs, pulmonary function test and HRCT.  Thiry, SLE patients 
were questioned about their symptoms of respiratory disease or not. After 
clinical examination, patient underwent lab investigations and imaging 
modalities. On analyzing the results from the study two-thirds of the 
patients had respiratory abnormalities. It was found that longer the 
duration of the disease, more likelihood of developing pulmonary 
pathology. HRCT is more sensitive in detecting the anatomical 
abnormalities than any other non–invasive investigating modality. 
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ABBREVIATIONS 
 
ACR  - American College of Rheumatology 
ANA  - Anti Nuclear Antibody 
ARDS  - Adult Respiratory Distress Syndrome 
BAL  -  Broncho Alveolar Lavage 
CD   - Cluster Differentiation 
COPD  - Chronic Obstructive Pulmonary Disease 
DLCO  - Diffusing Capacity of  Carbonmonoxide 
DVT  - Deep vein thrombosis 
FRC    - Functional Residual Capacity 
FEV  - Forced Expiratory Volume 
FVC   - Forced Vital Capacity 
HRCT  - High Resolution Computed Tomography 
ILD   - Interstitial Lung Disease 
Ig     - Immunoglobulin 
LE   - Lupus Erythematosus 
MVV   - Maximum voluntary ventilation 
PFT   - Pulmonary Function Test 
PHT   - Pulmonary Hypertension 
PE  - Pulmonary embolism 
RV   - Residual Volume 
RA   - Rheumatoid Arthritis 
SLE   - Systemic Lupus Erythematosus 
TV   - Tidal Volume 
TLC   - Total Lung Capacity 
V/Q   - Ventilation /Perfusion 
 82 
                                    PROFORMA 
 
 
DATE: 
 
NAME:                                  AGE:    SEX: 
 
OCCUPATION: 
 
ADDRESS: 
 
FIRST VISIT ON: 
 
NO OF YEARS AFTER DIAGNOSIS OS SLE: 
 
Presenting problems at the first visit: 
 
PAST ILLNESS: 
   
     H/o. Diabetes 
     H/o. Hypertension 
     H/o. Ischemic Heart Disease 
     H/o. Pulmonary Tuberculosis 
     H/o. COPD 
 
PERSONAL HISTORY:   
 
      H/o. Smoking: 
 
FAMILY HISTORY: 
 
LABORATORY INVESTIGATIONS DONE AT THE TIME OF 
DIAGNOSIS: 
 
DETAILS OF TREATMENT: 
 
NATURAL HISTORY OF DISEASE SINCE DIAGNOSIS : 
 
PATIENTS IS AT PRESENT ON DRUGS: 
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EXAMINATION ON: 
 
   Presenting Problems Now: 
 
    H/o. Breathlessness: 
 
    H/o. Cough: 
 
    H/o. Chest Pain 
 
    H/o. Hemoptysis 
 
General Examinations: 
 
PR:                    BP: 
 
CVS: 
 
 
RS: 
 
 
ABDOMEN: 
 
 
CNS: 
 
INVESTIGATIONS 
 
CHEST X RAY: 
 
 
PULMONARY FUNCTION TEST: 
 
HIGH RESOLUTION COMPUTED TOMOGRAPHY OF CHEST: 
 
 
MISCELLANEOUS INVESTIGATIONS:  
 
FINAL DIAGNOSIS: 
MASTER CHART 
 
PFT 
Sn 
Name and 
IP No. 
Age Sex 
Duration 
Since 
diagonosis 
Of SLE 
Duratio
n of RS 
sympto
ms 
 
Cough Dyspnea 
Clinic 
Exam 
CXR FEV1 
% 
FVC 
% 
FEV1/ 
FVC% 
RV 
% 
IC 
% 
TLC 
% 
Interpretation HRCT 
1 
Venilla 
780925 
25 F 5 years 6 months - + Normal Normal 62 54 104 26 87 46 Normal Bullous lesion poster basal seg.Left LL 
2 
Subbulakshmi 
782933 
22 F 1 year - - - Normal Normal 76 92 78 147 135 107 
Mild air flow 
limitation 
gastrapping 
0.43L 
Normal 
3 
Sanhara 
782657 
12 F 1 year - - - Normal 
Consolidati
on R 
powerzone 
74 78 94 40 110 65 Mild restriction 
vol loss 0.88L 
Pneumonic changes 
postero basal 
segment R lower lobe 
4 
Shanthi 
781020 
14 M 2 years 2  
months + + 
Reduced 
breath 
sound both 
axillae 
B/L pleural 
effusion 65 60 104 84 91 92 Normal B/L pleural effusion 
5 
Ramya 
781084 
18 F 2 years - - - Normal Normal 67 66 100 48 94 61 
Moderate 
restrictive 
pattern 
Patchy consolidation 
& pleuralthickening 
posterior segment let 
LL 
6 
Saroja 
780177 
21 F 3  years 1 month - + 
Reduced 
breath 
sounds both 
bases 
Haziness 
both lower 
zones 
84 66 108 21 78 54 
Moderate 
restrictive 
pattern vol.loss 
1.09L 
B/L  Pleural Effusion 
7 Kanmani 779908 14 F 2 years - - - Normal Normal 47 44 104 22 59 38 
Severe 
restriction vol. 
Loss 1.82L 
B/L ground glass 
shadow posterobasal 
segments 
8 Logaranjini 779275 14 F 2 years - - - Normal Normal 77 71 108 30 91 61 
Mild restriction 
vol.loss IL Normal 
9 Thenmozhi 777618 18 F 2 years 1 month + + 
B/L 
Bronchial 
Breathing 
Fine creps 
B/L 
Consolidati
on air 
Bronchogra
m 
90 81 102 44 103 72 Mild restrictive pattern 
B/L Basal 
pneumonitic pleural 
effusion 
10 Jansirani 777361 20 F 4 years  1 Year - + 
Creps both 
bases 
Haziness 
both lower 
zones 
cardiomega
ly 
 
30 23 130 8 18 19 
Combined 
pattern vol.loss 
2.19L 
B/L ground glasss 
shadow 
11 suganthamani 21 F 2 years 1 month - + normal 
B/L lower 
zone 
haziness 
cardiomega
ly 
39 32 111 9 30 26 
Severe 
restrictive vol 
loss 2.11L 
Pericardial effusion 
12 Nagammal 775789 23 F 3 years 1 month + + normal 
Haziness 
right lower 
zone 
35 36 96 50 74 94 Combined pattern 
Pneumonitic lateral 
base segment  
13 Indrakumari 775321 21 F 1 year 6 weeks - + Normal 
Prominent 
Pulmonary 
vessels 
93 79 109 29 54 65 
Mild restrictive 
pattern vol.loss 
1.11L 
Ground glass 
shadows prominent  
pulmonary vessels 
14 Uthra 774467 27 F 2 years 1 year - + Normal Normal 67 63 100 36 81 54 
Combined 
pattern mild 
airflow 
limitation 
Normal 
15 Baby 774153 47 F 3 years  1 year - + B/L creps Normal 54   43 116 7 59 32 
Severe 
restrictive vol. 
loss 
Normal 
16 Saroja 
 
24 M 2 years  - - - 
Fine creps 
R infra 
axillary 
region 
Normal 19 88 23 593 97 206 
Moderate 
restriction 
vol.loss IL 
Normal 
17 Radhika 771661 25 F 5 years 4 months  + + Normal Normal 57  50 105 27 51 43 
Severe 
restrictive 
pattern  vol. 
loss l.93L 
Normal 
18 Dhanalaxmi 772340 23 F 2 years 1 month + - Normal 
Haziness 
both lower 
zones 
64 53 114 11 68 42 
Severe 
restrictive 
pattern vol loss 
1.78L 
B/L ground glass 
shadow 
19 Logaranjani 
 
24 F 3 years - - - Normal Normal 65 49 132 16 69 40 Combined  pattern 
Cavitary lesion L 
lower lobe 
20 Subatha 770745 28 F months 1 month + _ 
Coarse 
creps both 
bases 
Normal 73 77 84 50 94 64 
Moderate 
restriction 
vol.loss  1.09L 
Normal 
21 Njamma 770621 29 F 6 years 1 year - + Normal Normal 64 66 96 19 93 51 
Combined  
pattern air flow 
limitation 
vol.loss 1.45 L 
B/L ground glass 
shadows subpleural 
reticulation 
22 Gulab John 770352 53 F 5 years 1 year - + Normal 
Castophreni
c angle 
obliteration 
L side 
50 34 132 5 51 23 
Severe 
restrictive 
pattern vol. 
Loss 2.4L 
Diffuse micronodular 
opacities B/L ground 
glass shadows B/L 
23 Shankari 768945 27 F 3 years - - - Normal Normal 69 98 101 210 124 126 
Air flow 
limitation Normal 
24 Amuda 767513 18 M 1 year  1 month - + 
Creps both 
bases Normal 75 74 101 60 82 88 Normal Normal 
25 Alamelu 767486 52 F 5 years 1 year + + Fine creps Normal 75 40 196 40 29 61 
Severe 
restrictive 
pattern 
B/L ground glass 
shadow 
26 Poornima 766778 22 F 2 years  - - - Normal Normal 77 70 107 34 70 60 Normal Normal 
27 Rekha 765400 23 F 3 years  6 months - + Normal Normal 54 73 68 143 70 92 
Mild air flow 
limitation Normal 
28 Valarmathi 763174 20 F 3 years - - - Normal Normal 76 74 101 47 110 67 
Mild restrictive 
pattern vol.loss 
1.11L 
Normal 
29 Radhika 762908 34 F 3 years  1 year - + B/L creps  Normal 54 43 116 7  59 32 
Severe 
restrictive 
pattern vol.loss 
2.18 
Severe restrictive 
pattern 
30 Sumathi 762880 41 F 2 years  - - - Normal Normal 74 23 288  6 51 17 
Severe 
restrictive 
vol.loss 2.79 L 
B/L ground glass 
shadow postero basal 
segments. 
 
